{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:06:49Z","timestamp":1776179209565,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-025-01349-7","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T16:26:36Z","timestamp":1739031996000},"page":"413-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States"],"prefix":"10.1007","volume":"15","author":[{"given":"Shawn G.","family":"Kwatra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashis K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Paydar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donia","family":"Bahloul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan B.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"6","key":"1349_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1349_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","volume":"14","author":"KA Williams","year":"2021","unstructured":"Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67\u201377.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"1349_CR3","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","volume":"141","author":"S Wongvibulsin","year":"2021","unstructured":"Wongvibulsin S, Sutaria N, Williams KA, et al. A nationwide study of prurigo nodularis: disease burden and healthcare utilization in the United States. J Invest Dermatol. 2021;141(10):2530-33.e1.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1349_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-83.e4.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1349_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jaad.2021.09.028","volume":"86","author":"N Sutaria","year":"2022","unstructured":"Sutaria N, Adawi W, Brown I, et al. Racial disparities in mortality among patients with prurigo nodularis: a multi-center cohort study. J Am Acad Dermatol. 2022;86(2):487\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1349_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","volume":"37","author":"N Weigelt","year":"2010","unstructured":"Weigelt N, Metze D, St\u00e4nder S. Prurigo nodularis: systematic analysis of 58\u00a0histological criteria in 136 patients. J Cutan Pathol. 2010;37(5):578\u201386.","journal-title":"J Cutan Pathol"},{"key":"1349_CR7","unstructured":"DUPIXENT. Prescribing information. Regeneron Pharmaceuticals Inc; 2024. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 24 Apr 2024."},{"issue":"3","key":"1349_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"1349_CR9","unstructured":"NEMLUVIO. Prescribing information. Galderma Laboratories; 2024. https:\/\/www.galderma.com\/sites\/default\/files\/2024-08\/Nemluviouspippi0812.pdf. 2024. Accessed 3 Sep 2024."},{"issue":"9","key":"1349_CR10","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1016\/j.jaip.2020.05.051","volume":"8","author":"KA Whang","year":"2020","unstructured":"Whang KA, Mahadevan V, Bakhshi PR, et al. Prevalence of prurigo nodularis in the United States. J Allergy Clin Immunol Pract. 2020;8(9):3240\u20131.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1349_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bjd.18925","volume":"183","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Williams KA, Grossberg AL, Kwatra MM, Kwatra SG. Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. Br J Dermatol. 2020;183(1):182\u20134.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1349_CR12","first-page":"88","volume":"6","author":"KA Whang","year":"2019","unstructured":"Whang KA, Kang S, Kwatra SG. Inpatient burden of prurigo nodularis in the United States. Medicines (Basel). 2019;6(3):88.","journal-title":"Medicines (Basel)"},{"issue":"3","key":"1349_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","volume":"86","author":"KA Whang","year":"2022","unstructured":"Whang KA, Le TK, Khanna R, et al. Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol. 2022;86(3):573\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1349_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/ced.14652","volume":"46","author":"N Sutaria","year":"2021","unstructured":"Sutaria N, Choi J, Roh YS, et al. Association of prurigo nodularis and infectious disease hospitalizations: a national cross-sectional study. Clin Exp Dermatol. 2021;46(7):1236\u201342.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1349_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283\u20139.","journal-title":"Dermatol Clin"},{"issue":"4","key":"1349_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.jaip.2017.10.024","volume":"6","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Qureshi AA, Amand C, et al. Health care resource utilization and costs among adults with atopic dermatitis in the United States: a claims-based analysis. J Allergy Clin Immunol Pract. 2018;6(4):1342\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"1349_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/pds.4165","volume":"26","author":"MS Cepeda","year":"2017","unstructured":"Cepeda MS, Fife D, Denari\u00e9 M, Bradford D, Roy S, Yuan Y. Quantification of missing prescriptions in commercial claims databases: results of a cohort study. Pharmacoepidemiol Drug Saf. 2017;26(4):386\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01349-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:10:53Z","timestamp":1739837453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01349-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01349-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shawn G. Kwatra is an advisory board member\/consultant for AbbVie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals Inc, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Ashis K. Das, Eunice Chang, and Caleb Paydar are employees of PHAR. Donia Bahloul is an employee and stockholder of Sanofi. Chao Chen and Ryan B. Thomas are employees and stockholders of Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data in IQVIA PharMetrics\u00ae Plus datasets are HIPPA (1996) compliant and deidentified to adhere with all relevant US regulations and privacy laws. As such, this study only analyzed deidentified data, which are a priori exempt from Institutional Review Board approval according to the Federal Policy for the Protection of Human Subjects \u201cCommon Rule\u201d (1991, revised 2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}